| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT04847453 Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or… |
date change Primary completion pushed: 2026-06-30 -> 2028-06-30 |
| 2026-06-12 | NCT04847453 Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or… |
date change Completion pushed: 2026-06-30 -> 2028-06-30 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT05722405 | Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of… | Multiple Myeloma | Recruiting |
| Phase 2 | |||
| NCT04305691 | Trial of Ixazomib for Kaposi Sarcoma | Kaposi Sarcoma | Recruiting |
| NCT03587662 | Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or… | Metastatic Kidney Medullary Carcinoma | Active, Not Recruiting |
| NCT02339922 | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin… | Chronic Lymphocytic Leukemia | Active, Not Recruiting |
| NCT03763162 | Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and… | Recurrent Plasma Cell Myeloma | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT04094961 | Ixazomib + Pomalidomide + Dexamethasone In MM | Multiple Myeloma | Active, Not Recruiting |
| NCT02343042 | Selinexor and Backbone Treatments of Multiple Myeloma Patients | Multiple Myeloma | Active, Not Recruiting |
| Phase 1 | |||
| NCT03283917 | Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis | Newly Diagnosed Primary Amyloidosis | Active, Not Recruiting |
| NCT04847453 | Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or… | Recurrent AL Amyloidosis | Active, Not Recruiting |